Published: 2nd June 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
The IVDR Submission Deadline Has Passed — But the Real Work Is Just Beginning
The 26 May 2026 IVDR Class C submission deadline marked a major milestone for IVD manufacturers across Europe. Thousands of companies rushed to finalise technical documentation, Performance Evaluation Reports (PERs), Quality Management System updates, and Notified Body applications before the cut-off date.
Now, many manufacturers find themselves in a new phase of the IVDR journey: the waiting room.
Submitting your application does not guarantee uninterrupted EU market access. In reality, the months following submission are often where the most critical compliance risks emerge. Delayed responses, incomplete application notices, contract issues, and technical documentation deficiencies continue to prevent many Class C IVD manufacturers from progressing toward certification.
This article explains what happens after IVDR Class C submission, what timelines to realistically expect, and the key actions manufacturers must take now to avoid losing market access.
New to the IVDR?
This article focuses on the post-submission stage for Class C IVDs. If you're looking for a complete overview of the EU In Vitro Diagnostic Regulation, including classification, performance evaluation, technical documentation, CE marking, UDI and compliance requirements, explore our Complete EU IVDR Guide.
What Happens After an IVDR Class C Submission?
For many manufacturers, there is a misconception that once the application is submitted, the hard part is over.
Under the EU IVDR (Regulation (EU) 2017/746), the post-submission phase is often more demanding than the initial application process itself.
Most manufacturers will now enter one of several stages:
- Administrative review
- Completeness check
- Technical documentation assessment
- Performance evaluation review
- QMS assessment
- Corrective action cycles
- Certification decision
The entire process can take anywhere from 12 to 18 months — and in some cases longer depending on:
- Notified Body capacity
- Device complexity
- Documentation quality
- Responsiveness to deficiencies
- Number of devices in the application scope
Unsure Why Your IVD Is Class C?
This article focuses on what happens after submitting an IVDR Class C application. If you're unsure how your IVD is classified under Regulation (EU) 2017/746, including how the seven IVDR classification rules are applied and how to determine whether your device is Class A, B, C or D, explore our Complete Guide to IVDR Classification.
Understanding the 12–18 Month IVDR Review Timeline
Why IVDR Reviews Take So Long
Unlike the previous IVDD framework, the IVDR requires significantly deeper scrutiny of:
- Scientific validity
- Analytical performance
- Clinical performance
- Risk management
- PMS systems
- Usability engineering
- Stability evidence
- Manufacturing controls
Notified Bodies are now conducting far more detailed technical reviews than ever before.
For Class C IVDs, this means manufacturers should prepare for:
- Multiple rounds of questions
- Requests for clarification
- Additional evidence requests
- CAPA requirements
- Expanded technical assessments
Understand Your Ongoing Obligations Under Article 10 of the IVDR
Submitting your IVDR Class C application is only one step in the compliance journey. Learn more about Article 10 of EU IVDR 2017/746, including manufacturer responsibilities for quality management systems, technical documentation, performance evaluation, post-market surveillance, vigilance and maintaining compliance throughout the entire device lifecycle.
Typical IVDR Review Stages After Submission
1. Administrative Completeness Review
This is usually the first step after submission.
The Notified Body checks whether:
- Required forms are completed
- Technical documentation is present
- QMS certificates are included
- Device lists are accurate
- Application scope is clearly defined
At this stage, manufacturers commonly receive:
- Requests for missing documents
- Clarification requests
- Incomplete Application notices
2. Technical Documentation Assessment
Once accepted administratively, the technical review begins.
This includes detailed evaluation of:
- Performance Evaluation Reports (PERs)
- Scientific validity evidence
- Stability studies
- Risk management files
- IFUs and labelling
- PMS documentation
- PMPF plans
- Software validation
- Usability engineering
This phase can take many months depending on the number of products submitted.
Preparing for a Notified Body Performance Evaluation Review?
Performance Evaluation is a major part of the IVDR technical documentation assessment. Learn how to structure scientific validity, analytical performance and clinical performance evidence, prepare your PEP and PER, and maintain evidence through PMPF in our Complete Guide to IVDR Performance Evaluation.
3. Quality Management System (QMS) Review
Notified Bodies also assess whether the manufacturer’s ISO 13485 QMS adequately supports IVDR requirements.
Common focus areas include:
- Supplier controls
- PMS integration
- Vigilance procedures
- Change management
- UDI implementation
- Complaint handling
- Clinical evidence maintenance
Need Expert Support with Your IVDR Compliance Strategy?
Successfully navigating the IVDR conformity assessment process often requires specialist regulatory expertise. Discover how our IVD Consultancy Services can support your organisation with IVDR classification, technical documentation, performance evaluation, ISO 13485 Quality Management Systems, Notified Body interactions and ongoing regulatory compliance.
4. Non-Conformity and CAPA Cycles
Few IVDR applications pass without deficiencies.
Manufacturers should expect:
- Major non-conformities
- Minor non-conformities
- Requests for additional evidence
- CAPA implementation deadlines
Response times are critical. Delayed or incomplete responses can significantly extend timelines.
The Most Common Delay: “Incomplete Application” Notices
What Is an Incomplete Application Notice?
One of the most common reasons IVDR projects stall is because the application fails the initial completeness review.
An “Incomplete Application” notice means the Notified Body believes essential documentation or information is missing before formal review can begin.
This does not necessarily mean the submission has failed — but it can create major delays.
Common Reasons Manufacturers Receive Incomplete Application Notices
Typical causes include:
- Missing Performance Evaluation documentation
- Incorrect device classification rationale
- Incomplete Annex II/III documentation
- Poorly structured technical files
- Missing PMS procedures
- Inconsistent intended purpose statements
- Missing software validation evidence
- Inadequate risk management linkage
- Unclear device grouping rationale
Many manufacturers underestimate the importance of:
- Document traceability
- Cross-referencing
- Consistency across files
- Structured submission formatting
How to Respond to an Incomplete Application Notice
If you receive an incomplete application notification:
- Respond immediately
- Clarify timelines with your Notified Body
- Prioritise high-risk gaps first
- Maintain documented communication trails
- Ensure updated files are version controlled
- Conduct internal peer reviews before resubmission
Fast and well-organised responses can prevent months of unnecessary delays.
The September 2026 Contract Deadline: The Critical Next Step
Why the Signed Contract Matters
One of the biggest misunderstandings in the IVDR transition is the belief that submission alone protects market access.
In reality, manufacturers must also ensure a formal written agreement with a Notified Body is signed by September 2026.
Without a signed agreement in place, many transitional provisions may no longer apply.
This could place continued EU market access at risk.
What Happens If You Miss the Contract Deadline?
Manufacturers without signed agreements may face:
- Loss of transitional protection
- Product withdrawal requirements
- Distribution interruptions
- Importer uncertainty
- Increased regulatory scrutiny
- Potential loss of CE marking continuity
Given current Notified Body capacity constraints, securing contractual arrangements early is essential.
Why Notified Body Capacity Remains a Major IVDR Risk
Even after the May 2026 deadline, the IVDR bottleneck is far from resolved.
Many Notified Bodies continue to experience:
- Resource shortages
- Long technical review queues
- Delayed audit scheduling
- Specialist reviewer shortages
- Increasing application complexity
Manufacturers should expect prolonged timelines throughout 2026 and potentially into 2027.
Key Areas Manufacturers Should Focus on Right Now
1. Maintain Technical Documentation Readiness
Do not assume submitted files are “finished.”
Your team should continue updating:
- PMS data
- Vigilance records
- PER literature reviews
- Stability evidence
- Risk management files
Many Notified Bodies request updated evidence during review.
2. Prepare for Deficiency Questions Early
Develop internal response procedures now.
This includes:
- Assigning regulatory owners
- Creating document tracking systems
- Establishing response timelines
- Coordinating SMEs
- Preparing CAPA workflows
Rapid responses improve review efficiency.
3. Monitor Contract Status Carefully
Manufacturers should maintain direct visibility over:
- Contract negotiations
- Scope confirmations
- Device lists
- Review timelines
- Audit scheduling
Delays in administrative processes can become regulatory risks.
4. Strengthen Post-Market Surveillance Systems
Notified Bodies are placing growing emphasis on:
- Trend reporting
- PMS plans
- PMPF activities
- Vigilance integration
- Benefit-risk monitoring
Weak PMS systems remain a major source of IVDR non-conformities.
Prepare for Your Post-Market Surveillance Obligations
IVDR compliance continues after conformity assessment and market placement. Manufacturers need a structured Post-Market Surveillance (PMS) system to collect and evaluate information on device safety and performance, identify emerging risks and maintain regulatory documentation throughout the device lifecycle. Explore PMS Plans, PMS Reports, PSURs, vigilance and their relationship with PMPF in our Complete Guide to Post-Market Surveillance for Medical Devices and IVDs.
IVDR Compliance Doesn't End with Submission
Submitting your Class C IVD for conformity assessment is an important milestone, but manufacturers must also prepare for ongoing post-market obligations. Post-Market Performance Follow-up (PMPF) provides a structured process for proactively collecting and evaluating performance and scientific data throughout the device lifecycle. Learn how to develop a PMPF Plan, select appropriate activities and document your findings in our Complete Guide to IVDR Post-Market Performance Follow-up (PMPF).
Frequently Asked Questions about EU IVDR deadlines
Does submitting before May 26 guarantee market access?
No. Submission alone is not enough. Manufacturers must still progress through technical review and ensure signed Notified Body agreements are in place within required timelines.
How long does an IVDR technical documentation review take?
Most reviews currently take approximately 12–18 months depending on:
- Device complexity
- Application quality
- Reviewer availability
- Number of deficiencies raised
What is the biggest cause of IVDR delays?
Incomplete applications and poorly structured technical documentation remain the most common causes of delays.
Can products remain on the market during review?
Potentially yes, provided transitional requirements are met and contractual obligations with the Notified Body remain compliant.
Don't Miss the Remaining IVDR Transitional Milestones
Submitting your IVDR Class C application is only one milestone in the transition to full IVDR compliance. Read our IVDR Transitional Provisions 2026 Milestones Guide to understand the remaining application deadlines, written agreement requirements, transitional provisions and the actions manufacturers must take to maintain EU market access.
Final Thoughts: Submission Was the Beginning — Not the Finish Line
For many IVD manufacturers, the May 2026 submission deadline felt like the end of a marathon.
In reality, it was only the beginning of the certification journey.
The next 12–18 months will determine whether manufacturers successfully achieve IVDR certification or face costly delays, market disruption, and increased regulatory risk.
Organisations that remain proactive — particularly around technical documentation quality, deficiency management, PMS systems, and contract readiness — will be best positioned to maintain uninterrupted EU market access.
Need Help Managing Your IVDR Submission?
At Patient Guard Ltd, we support IVD manufacturers throughout every stage of the IVDR transition process.
Our regulatory experts can help with:
- IVDR technical documentation remediation
- Performance Evaluation Reports (PERs)
- Gap analyses
- Deficiency response support
- PMS and PMPF systems
- Notified Body readiness
- ISO 13485 integration
- Risk management alignment
- Regulatory strategy planning
If your organisation is currently navigating the post-submission review phase, our team can help reduce delays and strengthen your pathway to certification.
Contact Patient Guard Ltd Today for IVDR Support and Strategic Guidance
References
This guide is based on the following legislation, international standards and official regulatory guidance relating to IVDR Class C conformity assessment, post-submission review and ongoing regulatory compliance.
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR) | Provides the legal framework governing conformity assessment, Quality Management Systems, performance evaluation, technical documentation and post-market obligations for in vitro diagnostic medical devices. |
| European Union | Regulation (EU) 2024/1860 | Amends the IVDR transitional provisions by introducing revised transition timelines and milestone requirements, including the application and written agreement deadlines discussed throughout this article. |
| European Commission | MDCG Endorsed Documents and Other Guidance | Provides official Medical Device Coordination Group (MDCG) guidance supporting IVDR conformity assessment, technical documentation, performance evaluation and transition requirements. |
| European Commission | Notified Bodies for Medical Devices | Provides official information on the designation and responsibilities of Notified Bodies carrying out IVDR conformity assessment and certification. |
| International Organization for Standardization (ISO) | ISO 13485:2016 – Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes | Defines the internationally recognised Quality Management System requirements assessed by Notified Bodies during IVDR conformity assessment. |
| International Organization for Standardization (ISO) | ISO 14971:2019 – Medical Devices – Application of Risk Management to Medical Devices | Provides the internationally recognised framework for documenting and maintaining risk management throughout the conformity assessment and post-market lifecycle. |
IVDR legislation, conformity assessment requirements and regulatory guidance continue to evolve. Manufacturers should always consult the latest published legislation, recognised standards and official guidance when managing Notified Body reviews, responding to deficiencies and maintaining compliance throughout the IVDR certification process.
Patient Guards Recent Posts
DCB0129 and Clinical Safety: What Digital Health Manufacturers Need for NHS DTAC
For digital health manufacturers preparing to enter the NHS, clinical safety can be one of the most important—and sometimes misunderstood—parts of DTAC.
It is not enough to demonstrate that your software works.
Manufacturers need to consider what could happen if the technology fails, produces incorrect information, presents information incorrectly, contributes to a workflow error or is used in circumstances that could expose patients to harm.
This is where clinical risk management and DCB0129 become particularly important.
NHS England identifies DCB0129 as the clinical risk management standard for manufacturers of health IT systems. Its counterpart, DCB0160, applies to health organisations deploying and using health IT systems. NHS England states that compliance with these standards is required under the Health and Social Care Act 2012.
For manufacturers working towards NHS DTAC readiness, understanding the distinction—and having the right clinical safety evidence—is essential.
DTAC Requirements Explained: The 5 Areas Digital Health Manufacturers Need to Get Right
If your digital health technology is heading towards the NHS, understanding the Digital Technology Assessment Criteria (DTAC) should be part of your market-access planning.
But one of the biggest mistakes manufacturers can make is treating DTAC as simply another questionnaire to complete.
The questions are only part of the process.
Behind your answers needs to be evidence showing that your technology and organisation have appropriate arrangements for clinical safety, data protection, technical security, interoperability, and usability and accessibility.
These five areas form the core of NHS DTAC. NHS England describes DTAC as national baseline criteria for digital health technologies entering NHS and social care.
For digital health manufacturers, the practical question is therefore not simply:
“Can we complete the DTAC assessment?”
It is:
“Can we demonstrate that our product meets the requirements?”
This guide looks at each of the five DTAC areas, the types of evidence manufacturers should consider and some of the common gaps that can delay NHS readiness.
The Complete Guide to NHS DTAC Compliance for Digital Health Manufacturers
A complete guide to NHS DTAC compliance for digital health manufacturers, covering the five DTAC assessment areas, required evidence, clinical safety, data protection, technical security, interoperability and usability, and how to prepare your digital health technology for NHS procurement.
Patient Guards Related Services
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
